Pharmacodynamic effects of C-domainspecific ACE inhibitors on the reninangiotensin system in myocardial infarcted rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 4, 2015, Pages 1149-1158

  Sharp, Sarah ^a   Poglitsch, Marko ^b   Zilla, Peter ^a   Davies, Neil H ^a   Sturrock, Edward D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Vienna Biocenter   (Austria)

Author keywords

Angiotensin converting enzyme; LC MS MS; Lisinopril tryptophan; Myocardial infarction; Pharmacodynamics

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II [1-7]AMIDE[1 SARCOSINE]; ANGIOTENSIN II [5 ISOLEUCINE]; ANGIOTENSIN III [7 ISOLEUCINE]; ANGIOTENSINAMIDE; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LISW S; UNCLASSIFIED DRUG; ANGIOTENSIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; OLIGOPEPTIDE; PEPTIDE; SERASPENIDE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG RESPONSE; DRUG SELECTIVITY; ENZYME INHIBITION; HEART INFARCTION; HEART INFARCTION SIZE; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PROTEIN DOMAIN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECTS; METABOLOME; MYOCARDIAL INFARCTION; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; WISTAR RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANIMALS; LISINOPRIL; MALE; METABOLOME; MYOCARDIAL INFARCTION; OLIGOPEPTIDES; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; PROTEIN STRUCTURE, TERTIARY; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM;

EID: 84952887443     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320314568438     Document Type: Article

References (42)

1. Jessup M and Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018.
2. Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 2002; 89 (2A): 11A-16A; discussion 16A-17A.
3. Ma TK, Kam KK, Yan BP, et al. Renin-angiotensinaldosterone system blockade for cardiovascular diseases: Current status. Br J Pharmacol 2010; 160: 1273-1292.
4. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96, 712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 2000; 35: 1801-1807.
5. Rodrigues EJ, Eisenberg MJ and Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 2003; 115: 473-479.
6. Ehlers MR. Safety issues associated with the use of angiotensin- converting enzyme inhibitors. Expert Opin Drug Saf 2006; 5: 739-740.
7. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin- converting enzyme inhibitors. J Eval Clin Pract 2004; 10: 499-509.
8. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 2012; 110: 383-391.
9. Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002; 359: 2088-2089.
10. Emanueli C, Grady EF, Madeddu P, et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 1998; 31: 1299-1304.
11. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-1697.
12. Fuchs S, Xiao HD, Cole JM, et al. Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem 2004; 279: 15946-15953.
13. Fuchs S, Xiao HD, Hubert C, et al. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 2008; 51: 267-274.
14. Rousseau A, Michaud A, Chauvet MT, et al. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 1995; 270: 3656-3661.
15. Ehlers MR, Abrie JA and Sturrock ED. C domain-selective inhibition of angiotensin-converting enzyme. J Renin Angiotensin Aldosterone Syst 2013; 14: 189-192.
16. Denti P, Sharp SK, Kröger WL, et al. Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. Eur J Pharm Sci 2014; 56: 113-119.
17. Nchinda AT, Chibale K, Redelinghuys P, et al. Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme. Bioorg Med Chem Lett 2006; 16: 4616-4619.
18. Watermeyer JM, Kröger WL, O'Neill HG, et al. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem J 2010; 428: 67-74.
19. Burger D, Reudelhuber TL, Mahajan A, et al. Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension. Clin Sci 2014; 127: 57-63.
20. Schindler C, Bramlage P, Kirch W, et al. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag 2007; 3: 125-137.
21. Yugandhar VG and Clark MA. Angiotensin III: A physiological relevant peptide of the renin angiotensin system. Peptides 2013; 46: 26-32.
22. Kovarik JJ, Antlanger M, Domenig O, et al. Molecular regulation of the renin-angiotensin system in haemodialysis patients. Nephrol Dial Transplant 2015; 30: 115-123.
23. Poglitsch M, Domenig O, Schwager C, et al. Recombinant expression and characterization of human and murine ACE2: Species-specific activation of the alternative reninangiotensin- system. Int J Hypertens 2012; 2012: 428950.
24. Kadner K, Dobner S, Franz T, et al. The beneficial effects of deferred delivery on the efficiency of hydrogel therapy post myocardial infarction. Biomaterials 2012; 33: 2060-2066.
25. Davies N, Dobner S, Bezuidenhout D, et al. The dosage dependence of VEGF stimulation on scaffold neovascularisation. Biomaterials 2008; 29: 3531-3538.
26. Takagawa J, Zhang Y, Wong ML, et al. Myocardial infarct size measurement in the mouse chronic infarction model: Comparison of area- and length-based approaches. J Appl Physiol (1985) 2007; 102: 2104-2111.
27. Duncan AM, Burrell LM, Kladis A, et al. Effects of angiotensin- converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J Cardiovasc Pharmacol 1996; 28: 746-754.
28. Campbell DJ, Kladis A and Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-449.
29. Duncan AM, Burrell LM, Kladis A, et al. Angiotensin and bradykinin peptides in rats with myocardial infarction. J Card Fail 1997; 3: 41-52.
30. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril. Hypertension 2002; 39: E1-E8.
31. Rufaihah AJ, Haider HK, Sim KM, et al. Cardioprotective effect of des-Aspartate-angiotensin-I (DAA-I) on cytokine gene expression profile in ligation model of myocardial infarction. Life Sci 2006; 78: 1341-1351.
32. Wen Q, Sim MK and Tang FR. Reduction of infarct size by orally administered des-aspartate-angiotensin I in the ischemic reperfused rat heart. Regul Pept 2004; 120: 149-153.
33. Alghamri MS, Morris M, Meszaros JG, et al. Novel role of aminopeptidase-A in angiotensin-(1-7) metabolism post myocardial infarction. Am J Physiol Heart Circ Physiol 2014; 306: H1032-H1040.
34. Swanson GN, Hanesworth JM, Sardinia MF, et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 1992; 40: 409-419.
35. Yoshida M, Kikukawa M, Hisa H, et al. Modulation by nitric oxide and prostaglandin of the renal vascular response to angiotensin II (3-8). Br J Pharmacol 1996; 117: 885-890.
36. Ruiz-Ortega M, Lorenzo O and Egido J. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int 2000; 57: 2285-2298.
37. Wang H, Zhang Q, Zeng X, et al. Effects of angiotensin III on protein, DNA, and collagen synthesis of neonatal cardiomyocytes and cardiac fibroblasts in vitro. J Cardiovasc Pharmacol Ther 2010; 15: 393-402.
38. Yamamoto K, Chappell MC, Brosnihan KB, et al. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 1992; 19: 692-696.
39. Andrade M, Quinto B, Carmona A, et al. Purification and characterization of angiotensin I-converting enzymes from mesangial cells in culture. J Hypertens 1998; 16: 2063-2074.
40. Deddish P, Marcic B, Jackman H, et al. N-domain specific substrate and C-domain inhibitors of angiotensin converting enzyme. Hypertension 1998; 31: 912-917.
41. Allred AJ, Diz DI, Ferrario CM, et al. Pathways for angiotensin-( 1-7) metabolism in pulmonary and renal tissues. Am J Physiol Renal Physiol 2000; 279: F841-F850.
42. Chappell MC, Pirro NT, Sykes A, et al. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 1998; 31: 362-336.